von Tobias Borgers | Okt. 3, 2019 | Roche
Media Release Basel, 01 April 2019 Roche’s ipatasertib in combination with Tecentriq and chemotherapy shows promising anti-tumour activity in triple-negative breast cancer in early phase trial Data from Phase Ib study to be presented at American Association for Cancer...
von Tobias Borgers | Okt. 3, 2019 | Roche
Media Release Basel, 23 April 2019 Roche launches new VENTANA HER2 Dual ISH companion diagnostic test for breast and gastric cancer patients eligible for targeted therapy Nearly 2.1 million new cases of breast cancer are diagnosed worldwide each year, and more than...
von Tobias Borgers | Okt. 3, 2019 | Roche
Media Release Basel, 29 April 2019 New Roche data at the 2019 AAN Annual Meeting showcase breadth and promise of neuroscience portfolio Risdiplam data from Part 1 of pivotal FIREFISH study show infants with Type 1 spinal muscular atrophy achieve key motor milestones...
von Tobias Borgers | Okt. 1, 2019 | Roche
Media Release Basel, 11 June 2019 Changes in Roche’s Board of Directors and Corporate Executive Committee Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that Peter Voser (61), a member of the Board of Directors of Roche Holding Ltd since 2011, has decided to...
von Tobias Borgers | Sep. 6, 2019 | Roche
Media Release Basel, 31 January 2019 Roche reports very strong results in 2018 Group sales increase 7%1 at constant exchange rates and in Swiss francs Pharmaceuticals Division sales up 7%, driven mainly by Ocrevus, Perjeta, Tecentriq, Alecensa and Hemlibra Diagnostics...
von Tobias Borgers | Sep. 5, 2019 | Roche
Media Release Basel, 25 February 2019 Roche enters into definitive merger agreement to acquire Spark Therapeutics Roche to acquire Spark Therapeutics for US$ 114.50 per share Spark Therapeutics is a leader in discovering, developing and delivering gene therapies with...
